A detailed history of Marshall Wace, LLP transactions in Humacyte, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 584,562 shares of HUMA stock, worth $2.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
584,562
Previous 463,662 26.08%
Holding current value
$2.54 Million
Previous $2.23 Million 42.92%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.11 - $9.46 $617,799 - $1.14 Million
120,900 Added 26.08%
584,562 $3.18 Million
Q2 2024

Aug 14, 2024

BUY
$2.87 - $9.1 $1.29 Million - $4.1 Million
450,031 Added 3301.53%
463,662 $2.23 Million
Q1 2024

May 15, 2024

SELL
$2.57 - $4.84 $368,869 - $694,680
-143,529 Reduced 91.33%
13,631 $42,000
Q4 2023

Feb 14, 2024

SELL
$1.99 - $3.12 $37,903 - $59,426
-19,047 Reduced 10.81%
157,160 $446,000
Q3 2023

Nov 14, 2023

BUY
$2.75 - $4.48 $484,569 - $789,407
176,207 New
176,207 $516,000
Q3 2022

Nov 14, 2022

BUY
$1.22 - $5.14 $163,116 - $687,228
133,702 Added 227.28%
192,530 $628,000
Q2 2022

Aug 15, 2022

BUY
$3.21 - $7.86 $188,837 - $462,388
58,828 New
58,828 $189,000

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $447M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.